Table I.
Manufacturing method | Dosage form | API | Excipients | Effect | Ref. |
---|---|---|---|---|---|
Powder solidifcation | |||||
Drop on solid | Implant | Isoniazide |
Powder:
PLLA Ink: Acethone, Ethanole, Water |
Sustained release | (5) |
Tablets | Captopril |
Powders:
maltitol, maltodextrin, Ink: Water Polyvinylpyrrolidone |
Rapidly dispersing tablets | (6) | |
Selective laser sintering | Orodispersible tablets | Paracetamol | hydroxypropyl methylcellulose vinylpyrrolidone-vinyl acetate copolymer |
Orodispersible tablets, fast drug release | (7) |
Liquid solidification | |||||
Stereolithography | Tablets | Paracetamol 4-Aminosalicylic acid |
Poly(ethylene glycol) diacrylate, Poly(ethylene glycol) 300, diphenyl(2,4,6- trimethylbenzoyl) phosphine oxide |
Controlled release | (8) |
Microneedles | Insulin | Dental SG resin Xylitol, Mannitol, Trehalose |
Insulin skin delivery | (9) | |
Drop on drop | Tablets | Ropinirole HCl | Irgacure 2959 Poly(ethylene glycol) diacrylate |
Fickian diffusion API release mechanizm | (10) |
Tablets | Fenofibrate | White beeswax | Fickian diffusion API release mechanizm | (11) | |
Extrusion based methods | |||||
Fused deposition modelling | Orodispersible films | Aripiprazole | Polyvinyl alcohol | Fast disintegration and dissolution | (12) |
Tablets | Theophylline | Hydroxypropyl cellulose, Triacetin, Sodium starch glycolate, Croscarmellose sodium, Crospovidone, |
Immediate release | (13) | |
Extrusion at room temperature | Floating tablets | Dipyridamole | Hydroxypropyl methyl cellulose, Microcrystalline cellulose, Lactose, Polyvinyl pyrrolidone |
Sustained release, gastrofloating dosage form | (14) |
Multi-compartment tablet | Nifedypine, Captopril, Glipizide |
Polyethylene glycol 6000, Microcrystalline cellulose, Hydroxypropyl methylcelloluse, D-Mannitol, Lactose, Sodium starch glycolate, Croscarmellose sodium, Sodium chloride, Tromethamine |
Controlled release | (15) |